Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Chongqing Taiji Industry(Group) Co.,Ltd (600129.SS)
CNY17.98
+0.35 (+1.99%)
CN SHH Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 1 Taiji Road 408000
Chongqing, CN
Chongqing, CN
CEO
Zongbin Yu
Website
taiji.com
IPO
1997-11-18
ISIN CNE000000TQ2
Description
Chongqing Taiji Industry (Group) Co.,Ltd operates as a pharmaceutical enterprise, conducting business both within China and across international markets. The company focuses on the research, development, manufacturing, and distribution of traditional Chinese medicines and various health products. Its offerings are available in a wide array of formats, including tablets, oral liquids, syrups, dripping pills, granules, capsules, tinctures, and powders. The product line addresses a comprehensive range of health conditions and therapeutic areas. These include disorders of the digestive and respiratory systems, cardiovascular and cerebrovascular ailments, pediatric and gynecological health, systemic anti-infective agents and antibiotics, pain relief medications, orthopedic treatments, remedies for colds and coughs, and drugs for the endocrine and nervous systems. The firm's headquarters are situated in Chongqing, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
CNY17.98
+0.35 (+1.99%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
8M
Beta
0.23
Float Shares
335.75M
Free Float %
60.9%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.90% | -1.28% | -4.94% | -12.46% | -25.23% | -14.79% | -26.45% | -69.56% | +0.85% | -7.79% | +123.59% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
17.98
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
1.09
Distress
Piotroski F-Score
7 / 9
Strong
MOAT Score
1 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
1 / 5
Low
ROE Score
3 / 5
Medium
ROA Score
3 / 5
Medium
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-15.7% Q1'26: -10.6% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+359.3% ★ Q1'26: -7.7% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%-1.1% Q1'26: -21.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+3.2% Q1'26: +3.3% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+2.3% Q1'26: +2.7% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-0.3% ★ Q1'26: -3.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×19.18× Q1'26: 19.03× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
7.17B
est: 7.16B (+0.1%)
|
7.95B
est: 7.36B (+8.0%)
|
8.77B
est: 7.16B (+22.5%)
|
10.69B
est: 7.36B (+45.2%)
|
11.64B
est: 7.77B (+49.9%)
|
11.21B
est: 8.21B (+36.5%)
|
14.13B
est: 13.85B (+2.0%)
|
15.62B
est: 14.39B (+8.6%)
|
12.39B
est: 12.88B (-3.9%)
|
10.45B
est: 10.49B (-0.4%)
|
11.35B
11.35B – 11.35B
+8.2% YoY
|
12.26B
12.26B – 12.26B
+8.0% YoY
|
13.16B
13.16B – 13.16B
+7.3% YoY
|
| EBITDA |
-24.04M
est: 337.39M (-107.1%)
|
-132.93M
est: 346.65M (-138.3%)
|
599.49M
est: 337.39M (+77.7%)
|
668.10M
est: 346.65M (+92.7%)
|
487.26M
est: 365.85M (+33.2%)
|
92.57M
est: 386.67M (-76.1%)
|
973.91M
est: 652.13M (+49.3%)
|
1.44B
est: 746.29M (+93.2%)
|
757.55M
est: 668.28M (+13.4%)
|
335.62M
est: 544.22M (-38.3%)
|
588.77M
588.77M – 588.77M
+8.2% YoY
|
635.97M
635.97M – 635.97M
+8.0% YoY
|
682.68M
682.68M – 682.68M
+7.3% YoY
|
| EBIT |
-193.35M
est: 166.40M (-216.2%)
|
-328.14M
est: 170.97M (-291.9%)
|
395.57M
est: 166.40M (+137.7%)
|
451.64M
est: 170.97M (+164.2%)
|
241.25M
est: 180.44M (+33.7%)
|
-183.71M
est: 190.70M (-196.3%)
|
656.01M
est: 321.63M (+104.0%)
|
1.10B
est: 473.81M (+132.8%)
|
423.19M
est: 424.28M (-0.3%)
|
335.62M
est: 345.51M (-2.9%)
|
373.80M
373.80M – 373.80M
+8.2% YoY
|
403.77M
403.77M – 403.77M
+8.0% YoY
|
433.42M
433.42M – 433.42M
+7.3% YoY
|
| Net Income |
231.61M
est: 1.55B (-85.1%)
|
856.21M
est: 1.27B (-32.6%)
|
97.74M
est: 1.55B (-93.7%)
|
70.26M
est: 1.27B (-94.5%)
|
-70.83M
est: 306.29M (-123.1%)
|
66.07M
est: 406.53M (-83.7%)
|
354.38M
est: 355.02M (-0.2%)
|
822.12M
est: 747.78M (+9.9%)
|
26.65M
est: 590.24M (-95.5%)
|
120.57M
est: 177.77M (-32.2%)
|
286.09M
286.09M – 286.09M
+60.9% YoY
|
488.86M
488.86M – 488.86M
+70.9% YoY
|
644.41M
644.41M – 644.41M
+31.8% YoY
|
| SGA |
2.20B
est: 2.72B (-19.1%)
|
2.59B
est: 2.79B (-7.1%)
|
2.70B
est: 2.72B (-0.6%)
|
3.64B
est: 2.79B (+30.4%)
|
4.53B
est: 2.95B (+53.7%)
|
4.46B
est: 3.11B (+43.4%)
|
5.41B
est: 5.25B (+2.9%)
|
5.97B
est: 4.89B (+21.9%)
|
3.97B
est: 4.38B (-9.5%)
|
2.12B
est: 3.57B (-40.7%)
|
3.86B
3.86B – 3.86B
+8.2% YoY
|
4.17B
4.17B – 4.17B
+8.0% YoY
|
4.48B
4.48B – 4.48B
+7.3% YoY
|
| EPS |
0.54
est: 2.79 (-80.6%)
|
2.01
est: 2.28 (-11.8%)
|
0.23
est: 2.79 (-91.8%)
|
0.13
est: 2.28 (-94.3%)
|
-0.13
est: 0.55 (-123.1%)
|
0.12
est: 0.73 (-83.8%)
|
0.64
est: 0.64 (-0.2%)
|
1.48
est: 1.35 (+9.9%)
|
0.05
est: 1.06 (-95.5%)
|
0.22
est: 0.32 (-31.3%)
|
0.52
0.52 – 0.52
+60.9% YoY
|
0.88
0.88 – 0.88
+70.9% YoY
|
1.16
1.16 – 1.16
+31.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-11 | C+ | 2/5 | 1/5 | 3/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 2/5 | 3/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-30 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-29 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-28 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-27 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-24 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-23 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-22 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-21 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-20 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-17 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
| 2026-04-16 | C+ | 2/5 | 1/5 | 2/5 | 4/5 | 1/5 | 1/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-438.89M
OE per share TTM
-0.79
Owner's Yield
-5.12%
Maintenance CapEx ratio
373.64%
Maint CapEx / Avg PPE
37.4%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
Held by 20 ETFs in our universe
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 181.1K | 0.39% |
| 2 | Dimensional - Emerging Core Equity Market ETF DFAE | 0.00% | 120.2K | 0.29% |
| 3 | Dimensional World ex U.S. Core Equity 2 ETF DFAX | 0.00% | 134.5K | 0.28% |
| 4 | Schwab Emerging Markets Equity ETF SCHE | 0.00% | 109.1K | 0.06% |
| 5 | Vanguard FTSE Emerging Markets Shares ETF VGE.AX | 0.00% | 8.7K | 0.48% |
| 6 | Vanguard FTSE Emerging Markets All Cap Index ETF VEE.TO | 0.00% | 19.7K | 0.26% |
| 7 | Vanguard FTSE Emerging Markets ETF VWO | 0.00% | 971.5K | 0.06% |
| 8 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Accumulating VFEA.L | 0.00% | 24.4K | 0.17% |
| 9 | Vanguard FTSE Emerging Markets UCITS ETF (USD) Distributing VDEM.L | 0.00% | 24.4K | 0.17% |
| 10 | Vanguard Total World Stock ETF VT | 0.00% | 277.1K | 0.06% |
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
26.7K
Shares Outstanding
551.42M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Haiyan Cui | Deputy General Manager | — | female |
| Kang Chen | Deputy General Manager | — | male |
| Liwen Tan | Deputy General Manager | — | male |
| Qian Jiang | Deputy GM & Secretary of the Board of Directors | — | female |
| Yonghong Yuan | Deputy General Manager | — | male |
| Zongbin Yu | General Manager | — | male |
| Zunyi Liu | Financial Director & Accounting Supervisor | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 600129.SS
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
